SCHEMBL3400738

SCHEMBL3400738

Cn1c(C(=O)O)cnc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NAPRT Q6XQN6 1/20 0.35
KDM4E B2RXH2 3/20 0.35
MCL1 Q07820 2/20 0.35
GPR35 Q9HC97 1/20 0.35
GRN P28799 1/20 0.35
SORT1 Q99523 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
RAB9A P51151 1/20 0.34
HSD17B10 Q99714 4/20 0.33
GFER P55789 1/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
RHEB Q15382 1/20 0.32
HCAR2 Q8TDS4 3/20 0.32
HTT P42858 1/20 0.32
SIRT6 Q8N6T7 1/20 0.31
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17450551 0.78 KDM4E (0.41) MEN1KMT2AL3MBTL1KDM4EMCL1
SCHEMBL28299318 0.77 NAPRT (0.41) MEN1KMT2AL3MBTL1NAPRTTDP1
SCHEMBL7996974 0.77 KMT2A (0.38) MEN1KMT2AL3MBTL1KDM4EMCL1
SCHEMBL17450552 0.77 GPR35 (0.40) MEN1KMT2AL3MBTL1KDM4EMCL1
SCHEMBL19175805 0.75 CYP1A2 (0.44) MEN1KMT2AL3MBTL1KDM4EMCL1
SCHEMBL13982981 0.75 L3MBTL1 (0.38) MEN1KMT2AL3MBTL1KDM4EMCL1
SCHEMBL3496090 0.75 MCL1 (0.40) MEN1KMT2AL3MBTL1KDM4EMCL1
SCHEMBL8073258 0.75 L3MBTL1 (0.38) MEN1KMT2AL3MBTL1KDM4EMCL1
SCHEMBL25269986 0.75 ALDH1A1 (0.40) MEN1KMT2AL3MBTL1KDM4EMCL1
SCHEMBL3530488 0.74 HTT (0.55) RAB9AHSD17B10ALDH1A1HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747203-A4 SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2009-04-22 EP claimed
US-7507756-B2 Scalable synthesis of imidazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-24 US claimed
CN-1980896-A Scalable synthesis of imidazole derivatives JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 CN claimed
EP-1747203-A1 SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-31 EP claimed
WO-2005110998-A1 SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2005-11-24 WO claimed
US-20050250948-A1 Scalable synthesis of imidazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-11-10 US claimed
EP-4499632-A1 QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS ESCIENT PHARMACEUTICALS, INC. (US) 2025-02-05 EP disclosed
US-20250026735-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2025-01-23 US disclosed
CN-119095839-A Quinoline derivatives as modulators and related products of Mas-associated G protein receptor X2 伊赛恩特制药公司 2024-12-06 CN disclosed
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-14 US disclosed
US-12129243-B2 Modulators of Mas-related G-protein receptor X2 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2024-10-29 US disclosed
US-12129244-B2 Modulators of Mas-related G-protein receptor X2 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2024-10-29 US disclosed
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-15 US disclosed
CN-1980896-A Scalable synthesis of imidazole derivatives JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 CN disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed
EP-1747203-A1 SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-31 EP disclosed
WO-2006089076-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2006-08-24 WO disclosed
WO-2005110998-A1 SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2005-11-24 WO disclosed
US-20050250948-A1 Scalable synthesis of imidazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 MEN1 590/4885KMT2A 988/4885L3MBTL1 3414/4885
US-20050250948-A1 Scalable synthesis of imidazole derivatives ABL1, NOS2, FLT3 MEN1 980/4885KMT2A 1116/4885L3MBTL1 4177/4885
US-12129244-B2 Modulators of Mas-related G-protein receptor X2 and related products and methods MRGPRX2, MRGPRX1, MRGPRX4 MEN1 517/4885KMT2A 3664/4885L3MBTL1 4132/4885
US-20250026735-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS MRGPRX2, MRGPRX1, MRGPRX4 MEN1 517/4885KMT2A 3664/4885L3MBTL1 4132/4885
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 MEN1 590/4885KMT2A 988/4885L3MBTL1 3414/4885
US-12129243-B2 Modulators of Mas-related G-protein receptor X2 and related products and methods MRGPRX2, MRGPRX1, MRGPRX4 MEN1 517/4885KMT2A 3664/4885L3MBTL1 4132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.